Eruptive Keratoacanthomas Associated With Pembrolizumab Therapy.

@article{FreitesMartnez2017EruptiveKA,
  title={Eruptive Keratoacanthomas Associated With Pembrolizumab Therapy.},
  author={Azael David Freites-Mart{\'i}nez and Bernice Y. Kwong and Kerri E Rieger and Daniel G. Coit and Alexander Dimitrios Colevas and Mario E. Lacouture},
  journal={JAMA dermatology},
  year={2017},
  volume={153 7},
  pages={694-697}
}
Importance To our knowledge, there have been no previous reports of eruptive keratoacanthomas (KAs) in patients receiving pembrolizumab. Objective To report the cases of 3 consecutive patients with pembrolizumab-induced eruptive KAs and their management. Design, Setting, and Participants Case report study of 3 patients from 2 centers with pembrolizumab… CONTINUE READING